Severe Hidradenitis Suppurativa Treated With Infliximab Infusion

Adams, David R.; Gordon, Kenneth B.; Devenyi, Attila G.; Ioffreda, Michael D.

doi:10.1001/archderm.139.12.1540

Cited by 89 publications

(71 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Case reports and series of cases have suggested that infliximab may be an effective treatment for HS, although the drug has yet to be approved for this purpose. [6][7][8][9][10] In the case reported here, the patient is female and the condition began at puberty and was confined exclusively to the inframammary region. The treatment proposed was the systemic use of sulfamethoxazole-trimethoprim with a maintenance dose and gradual withdrawal, in addition to topical antibiotics.…”

Section: Discussionmentioning

confidence: 77%

Caso para diagnóstico

Vasconcelos

Fonseca

Obadia

2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

A hidradenite é uma inflamação crônica e supurativa das glândulas apócrinas. Ocorre mais frequentemente, nas mulheres, iniciando durante ou após a puberdade. Os locais mais acometidos são as axilas, porém, outras regiões ricas em glândulas apócrinas, podem ser comprometidas. A localização intermamária, de forma exclusiva, é rara e não encontramos relatos de outros casos semelhantes. Sua etiologia ainda não foi completamente elucidada

show abstract

Section: Discussionmentioning

confidence: 77%

Caso para diagnóstico

Vasconcelos

Fonseca

Obadia

2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…The most commonly used biologic cure was infl iximab, thus the most cases described were in connection with this biologic treatment. More authors in case reports (3,4,5,6) considering individual patients with morbus Crohn treated with infl iximab describe very good effect of infl iximab on the manifestations of hidradenitis suppurativa and long term remission of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…Adams et al (6) describes the case of 17 year patient with ulcerous colitis and HS. The patient was dosed with infl iximab in 0th, 2nd and 6th week.…”

Section: Discussionmentioning

confidence: 99%

Hidradenitis suppurativa treated with combination of infliximab and dapsone

Kozub¹,

Šimaljaková²

2012

BLL

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is chronic infl ammatory disease characterized by recurrent painful nodules, which leads to forming an abscess and sinus tracts, together with pustulation and hypertrophic scarring in the areas of apocrine sweat glands. Systemic and local antibiotic therapy, together with corticoid therapy, sulphonates, retinoids and surgical treatment with incisions and drainage belongs to actual treatment possibilities. Biological therapy represents the absolute peak in the treatment last years, mostly TNFα-inhibitors. Even though their very good short term effect is described, long term keeping up the good long effect of the treatment is not achieved with satisfaction. This is the reason to reach for traditional therapeutic possibilities combined with biological treatment in cases of torpid and resistive disease. In the following article a case report of a patient with hidradenitis suppurativa treated subsequently with combination of TNFα-inhibitors and dapson (Fig. 6, Ref. 19 Hidradenitis suppurativa (HS) is chronic infl ammatory disease characterized by recurrent painful nodules, which leads to forming an abscess and sinus tracts, together with pustulation and hypertrophic scarring in the areas of apocrine sweat glands. It is spread evenly between both genders. Obesity and smoking belong to risk factors. Hormonal factors are also described, which is supported by the fact, that the disease can be mitigated in gravidity. Various infections can worsen the existing manifestations. In clinical fi ndings painful nodules and fi stulas draining pus are seen. Predilection areas of the disease are the areas with apocrine glands (axillar and inguinal areas, perigenital and perianal area, submammar space), ectopic nodules can be located anywhere on the body. Sanation is accompanied with forming of hypertrophic scars, which can lead to dermogenous contractures. Systemic and local antibiotic therapy, together with corticoid therapy, sulfones, retinoids and surgical treatment with incisions and drainage belongs to actual treatment possibilities. Complete restoration is in the present possible only by removing the skin with apocrinne sweat glands in the full thickness, which can result in cosmetic disturbing features, dermogennous contractures and with predisposed individuals the new focus can appear in other part rich in apocrine sweat glands. Biologics, mainly TNFα-inhibitors, are even more often fi nding their place in the treatment of other diseases, where an important role is played by tumor necrosis factor alpha (TNFα). Hidradenitis suppurativa is one of these diseases. Case report53-years old female with two years history of hidradenitis suppurativa was admited at the Clinic of Dermatovenerology in Bratislava in March 2009. Painful nodules and many fi stulas in the medial part of thighs (Figs 1 and 2), left gluteal and submammar area were dominating the clinical fi ndings, ectopic focuses were found on the front side of the body. Axillar, perigenital and inguinal areas were not affected. Pati...

show abstract

“…Case-series of patients denoted a promising perspective (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Only three prospective, open-label, non-randomized studies have been published; one involving the administration of infliximab in 10 patients (18) and two involving the administration of etanercept in 10 and 15 patients, respectively (4,19).…”

Section: Discussionmentioning

confidence: 99%

Long‐term efficacy of etanercept in hidradenitis suppurativa: results from an open‐label phase II prospective trial

Πελεκάνου

Kanni

Savva

et al. 2010

Experimental Dermatology

View full text Add to dashboard Cite

Objective: To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.Methods: Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.Results: Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment. Conclusions:The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.

show abstract

Severe Hidradenitis Suppurativa Treated With Infliximab Infusion

Cited by 89 publications

References 14 publications

Caso para diagnóstico

Caso para diagnóstico

Hidradenitis suppurativa treated with combination of infliximab and dapsone

Long‐term efficacy of etanercept in hidradenitis suppurativa: results from an open‐label phase II prospective trial

Contact Info

Product

Resources

About